Enabling the most most productive AAV platform reach milions of patients around the world. Helping the most capable team to transfer the power of directed evolution to unlock the potential of genetic medicinesTransferring the Power of Directed Evolution to Unlock the Potential of Genetic Medicine

• Source, propose, structure and lead execution of clinically focused transactions with pharma, biotech, academic institutions• Own business case development, term sheet negotiation, due diligence and execution• Advise executive leadership, hone relationships with external networks of partners and key opinion leaders• Actively partner with other business functions including Commercial, R&D, Clinical Affairs, Marketing and Finance ensure a thorough evaluation of potential opportunities

Led the entirety of business development activities at a Seed Stage CRISPR genome editing start up, culminating in the $200M acquisition of the platform by Intellia Therapeutics.

Led end-to-end strategic business development activities at Berkeley Lights Inc, the leading digital cell biology platform prior to the company going public. Passionate about creative deal-making, including identification, evaluation, negotiation, execution and management of strategic partnerships. We help you discover, develop and manufacture better cells to improve existing or create new products in pharma, biotech, food, energy, agriculture and other industries.

Business development executive passionate about enabling breakthrough medications and technologies that help people live longer and suffer less. Lead strategic initiatives, search and evaluation projects, negotiations with a wide range of partners supporting $12B inorganic portfolio growth. Enjoy leading diverse teams to bring value through through thorough due diligence and creative deal making. Strive to help others grow.Selected projects: M&A: ViewicsSpin Out: Nimble Tx DaaS License: Molecular Match

As a Deal Team Lead I led a number of end-to-end business development projects: built strategy and internal alignment, scouted for opportunities, landscaped best options for partnering, conducted due diligence, supported or negotiated deals, including several in-licensing and M&A opportunities declined or lost. Identified and brought adjacent disruptive technologies that complement Roche business model. Scouted for and partnered with companies that created new or enabled established molecular modalities (small molecules, biologics, other). Aligned senior management on optimal ways to capture Healthcare IT opportunities worth pursuing to augment Roche portfolio in common and rare diseases. Led projects in all therapeutic areas of interest to Roche, including oncology, ophthalmology, neurology, infectious and rare diseases. • Aligned organization on development and implementation of Global Healthcare IT Strategy• Closed first two deals in Roche Partnering's history in Healthcare IT space • Closed four pilot studies with fully negotiated in-licensing / exclusivity rights• Led technical DD and managed pilot study leading to M&A transaction valued >$500M (Dutalys)

Devised strategies and ensured their execution to meet oncology patients needs in Russia, China, India, Turkey and over 30 other countries comprising Emerging Growth Markets.• Led Strategic Planning process in 34 countries resulting in the fastest out of 5 regions alignment with the global team• Created and moderated cross-functional steering committee expediting registration of the key future value generator in Russia • Led timely market authorization transfer between global Sandoz and Oncology teams• Conducted effective workshops for leadership team to adopt and implement global strategies locally• Executed on ad hoc requests from EGM Head, Global Oncology President, Pharma CEO and Group Leadership

Led consulting project to develop a global strategy maximizing the value of a multiple sclerosis drug launch. With 70% of recommendations implemented within a year, the drug reached $1B+ sales within 12 months after launch.

• Increased product utilization by over 150% at three customer sites• Negotiated contracts with existing clients achieving 100% license renewal rate• Capitalized on the largest market segment and increased profits by changing product portfolio mix• Developed and delivered product training program that customers consistently rated above 4.5 on a 5.0 scale• Analyzed and synthesized market data increasing executive team's alignment with customers

• Led seven solutions teams across 3 departments: received "best vendor" rating from 91% of clients• Initiated companywide turnaround program that resulted in 30% product quality improvement in 3 months• Closed gaps in new product, generating highest revenue in record time, $1m in 6 months• Created the most downloaded marketing collateral, leading to a 10-fold website traffic increase• Identified disruptive technology in the market and propped organization for change; resulting platform has beenhighest revenue generator for 3 years

•Identified new gene predisposing to Multiple Sclerosis •Redesigned pre-experimental procedures in two laboratories that reduced annual operating costs by 40% ($100K)•Increased throughput and reliability of genomic technique protocol, exceeding industry standard nearly twice •Trained and supervised two PhD students to plan and conduct high throughput experiments efficiently and independently using various genotyping technology platforms•Managed and analyzed data containing over 10M data points generated by four research groups using advanced statistical analysis methods that resulted in four publications in peer-reviewed journals•Consulted a group of IT specialists on Genetic Analysis-oriented database design•Conducted feasibility study for Remedium (Clinical Research Organization) regarding expansion of their operations to Eastern Europe

* Redesigned multiple sclerosis biomarker identification process in two labs, saving 40% ($100k)* Improved the throughput of a popular research protocol, exceeding industry standard two-fold

•Led a multinational team of 15 senior sales reps in former Soviet Union (CIS) with offices in Russia, Ukraine, Belarus, Georgia, Kazakhstan and Uzbekistan•Established enduring relationships with high net worth clients that increased sales 50% within existing accounts•Realigned staffing during major company restructuring, negotiated employment contracts in transition period•Improved productivity of the sales team that resulted in over 500% ($1M) revenue growth within a year

Identified a new target for drug-resistant HIV treatment